

# A H3K27M-targeted vaccine in adults with diffuse midline glioma

Received: 23 February 2023

Accepted: 22 August 2023

Published online: 21 September 2023

 Check for updates

Niklas Grassl <sup>1,2,3</sup>, Isabel Poschke <sup>1,4</sup>, Katharina Lindner <sup>1,4</sup>,  
Lukas Bunse <sup>1,2,3</sup>, Iris Mildenerberger<sup>1,2,3</sup>, Tamara Boschert <sup>1,4,5</sup>,  
Kristine Jähne<sup>1,2,3</sup>, Edward W. Green<sup>1,2,3</sup>, Ingrid Hülsmeier<sup>1,4</sup>, Simone Jünger<sup>1,4</sup>,  
Tobias Kessler<sup>6,7</sup>, Abigail K. Suwala<sup>8,9</sup>, Philipp Eisele<sup>2</sup>,  
Michael O. Breckwoldt <sup>1,3,10</sup>, Peter Vajkoczy<sup>11</sup>, Oliver M. Grauer <sup>12</sup>,  
Ulrich Herrlinger<sup>13</sup>, Joerg-Christian Tonn<sup>14</sup>, Monika Denk<sup>15</sup>, Felix Sahn <sup>8,9</sup>,  
Martin Bendszus<sup>10</sup>, Andreas von Deimling <sup>8,9</sup>, Frank Winkler<sup>6,7</sup>,  
Wolfgang Wick <sup>6,7</sup>, Michael Platten <sup>1,2,3,4,5,16</sup> ✉ & Katharina Sahn <sup>1,2,3,16</sup> ✉


Substitution of lysine 27 to methionine in histone H3 (H3K27M) defines an aggressive subtype of diffuse glioma. Previous studies have shown that a H3K27M-specific long peptide vaccine (H3K27M-vac) induces mutation-specific immune responses that control H3K27M<sup>+</sup> tumors in major histocompatibility complex-humanized mice. Here we describe a first-in-human treatment with H3K27M-vac of eight adult patients with progressive H3K27M<sup>+</sup> diffuse midline glioma on a compassionate use basis. Five patients received H3K27M-vac combined with anti-PD-1 treatment based on physician's discretion. Repeat vaccinations with H3K27M-vac were safe and induced CD4<sup>+</sup> T cell-dominated, mutation-specific immune responses in five of eight patients across multiple human leukocyte antigen types. Median progression-free survival after vaccination was 6.2 months and median overall survival was 12.8 months. One patient with a strong mutation-specific T cell response after H3K27M-vac showed pseudoprogression followed by sustained complete remission for >31 months. Our data demonstrate safety and immunogenicity of H3K27M-vac in patients with progressive H3K27M<sup>+</sup> diffuse midline glioma.

H3K27M<sup>+</sup> diffuse midline gliomas (DMGs) are aggressive, incurable primary central nervous system (CNS) tumors in children and young adults<sup>1</sup>. They are characterized by a clonal and mutually exclusive substitution of lysine 27 to methionine (K27M) in canonical (*H3.1/H3.2*) or noncanonical (*H3.3*) histone H3 (ref. 2) in anatomically distinct oligodendrocyte precursor cells<sup>3,4</sup>. As these tumors mainly form in midline CNS structures, surgical treatment options remain limited<sup>5,6</sup>. Response to chemoradiation is poor and palliative radiotherapy remains the only standard-of-care treatment with proven benefit<sup>6</sup>, resulting in a median overall survival (OS) between 10 and 15 months after initial diagnosis<sup>7</sup>. Immune checkpoint inhibitors (ICIs), such as PD-1 blockade

are successfully used in combinatorial immunotherapeutic approaches in high-grade gliomas<sup>8</sup>; however, in DMG intratumoral heterogeneity<sup>9</sup>, low PD-L1 expression<sup>10</sup>, low mutational burden<sup>11</sup> and the nature of chemotherapy-induced mutations<sup>12,13</sup> may explain why no survival benefit has been observed using ICI monotherapy<sup>14</sup> so far, though several clinical trials investigating the efficacy and safety of PD-1 blockade are ongoing (NCT02359565, NCT02793466, NCT03130959 and NCT01952769).

New immunotherapeutic approaches with specificity for DMG include disialoganglioside GD2-targeting chimeric antigen receptor (CAR) T cell therapy<sup>15</sup>, the oncolytic virus DNX-2401 (ref. 16)

A full list of affiliations appears at the end of the paper. ✉ e-mail: [m.platten@dkfz-heidelberg.de](mailto:m.platten@dkfz-heidelberg.de); [k.sahn@dkfz-heidelberg.de](mailto:k.sahn@dkfz-heidelberg.de)



**Fig. 1 | Patient characteristics at baseline and individual disease trajectories.** **a**, Baseline characteristics of eight patients with progressive DMG H3K27M<sup>+</sup> before initiation of treatment with H3K27M-vac. Age specified in years, tumor size measured as product of maximal orthogonal diameter on contrast-enhanced T1-weighted MRI sequences (mm<sup>2</sup>); cumulative dose of intensity-modulated radiotherapy measured in Gy; TMZ, temozolomide (75 mg m<sup>-2</sup> body surface area

(BSA)) daily during radiotherapy; CCNU, lomustine (110 mg m<sup>-2</sup> BSA d1, TMZ mg m<sup>-2</sup> BSA d2–6, q42d for six cycles); oral dexamethasone intake in mg d<sup>-1</sup>. Brain illustration taken from Adobe Stock Standard under License ID 222738500. **b**, Swimmer plot depicting clinical course since initial diagnosis, vaccine administration and time point of first H3K27M-specific immune responses in peripheral blood ( $n = 8$  patients).

and peptide vaccination<sup>17–19</sup>. A short H3.3K27M<sub>26–35</sub> peptide vaccine induced H3.3K27M-reactive CD8<sup>+</sup> T cells in human leukocyte antigen (HLA)-A\*02:01<sup>+</sup> patients with newly diagnosed H3.3K27M<sup>+</sup> DMG<sup>17</sup>. Whether such HLA-A\*02:01-restricted CD8<sup>+</sup> T cells recognize and kill HLA-A\*02:01<sup>+</sup> tumor cells expressing and processing endogenous H3.3K27M remains controversial<sup>17,19</sup>. We have previously shown that a long H3K27M<sub>14–40</sub> peptide vaccine, H3K27M-vac, induced CD4<sup>+</sup> T cell-mediated immune responses in a major histocompatibility complex (MHC)-humanized mouse tumor model<sup>18</sup>. Here, we present a first-in-human administration of H3K27M-vac to eight patients with progressive H3K27M<sup>+</sup> DMG.


## Results

A total of eight adult patients with progressive, histologically confirmed H3K27M<sup>+</sup> DMG after standard therapy options and not eligible to be enrolled in the currently ongoing multicenter, phase I clinical trial (NCT04808245) received H3K27M-vac on a compassionate use basis. Four patients were female and four patients were male (Fig. 1a), mean patient age was  $28.0 \pm 5.3$  years (mean  $\pm$  s.d.) and Karnofsky performance index (KPI) was at least 70% for all patients. All patients had unequivocal progressive disease (PD) as assessed by response assessment in neuro-oncology (RANO) criteria before the start of vaccinations. Tumors were located in the thalamus ( $n = 3$ ), the pons ( $n = 2$ ), the spinal cord ( $n = 2$ ) and the parietal lobe ( $n = 1$ ), with one patient having multilobar disease in the cerebellum and the lumbar

spinal cord. Two patients had undergone complete resection, three patients had partial resection and three patients had biopsies upon initial radiographic diagnosis. At first dosing, two patients took dexamethasone at a dose of 2 mg d<sup>-1</sup> and one patient took 4 mg d<sup>-1</sup> (Extended Data Table 1). All eight patients had previously received radiotherapy in 30 fractions to a total dose ranging from 54 to 60 Gy as well as chemotherapy with temozolomide. One patient (ID 7) received lomustine q42d following first PD and continued this therapy concomitant to vaccinations. Median tumor size as judged by the product of maximal orthogonal tumor diameter at baseline was  $407.8 \pm 589.4$  mm<sup>2</sup> (median  $\pm$  s.d.).

## H3K27M-vac was well tolerated

Patients received subcutaneous injections of H3K27M-vac bi-weekly for 6 weeks followed by monthly administration for 4 months and quarterly thereafter until PD (Fig. 1b, Fig. 2a and Supplementary Fig. 1). Five patients (62.5%) received H3K27M-vac in combination with anti-PD-1 dependent on the treating physician's discretion. Before each vaccination, adverse events (AEs) were assessed according to the Common Terminology Criteria for Adverse Events (CTCAE) v.5.0. In addition, the treatment schedule included monthly blood sampling for immune monitoring for 6 months and every 3 months thereafter as well as radiographic assessment every 3 months. Analysis of cerebrospinal fluid (CSF) was performed if clinically indicated (Fig. 2a). The duration of H3K27M-vac treatment ranged from 78 to 1,295 d (median 158 d)



**Fig. 2 | Treatment schedule, safety and immunogenicity of H3K27M-vac.** **a**, Treatment scheme for H3K27M-vac administration. **b**, Treatment-related AEs occurring in the observation period graded by CTCAE v.5.0. Two injection site reactions were related to H3K27M-vac and the remaining AEs were either judged to be related to concomitant medication or disease.

GGT, gamma-glutamyltransferase; ALT, alanine aminotransferase; AST, aspartate aminotransferase. **c**, T cell immune responses as a function of time measured by difference in mean spot-forming units (s.f.u.) in IFN- $\gamma$  ELISpot assay between  $4 \times 10^5$  peripheral blood mononuclear cells (PBMCs) stimulated with H3-mut and H3-wt control peptide.

and the duration of observation since the start of H3K27M-vac administration ranged from 191 to 1,414 d (median 391 d). Patients received a median of  $8 \pm 4.9$  (median  $\pm$  s.d.) vaccinations. One patient (ID 2) discontinued treatment with H3K27M-vac after eight vaccinations, but resumed treatment 20 months later. No regimen-limiting toxicity was observed during the observation period. Two patients (25%) experienced CTCAE grade 1 injection site reactions that were attributed to the treatment with H3K27M-vac (Fig. 2b). Eight other CTCAE grade 1 events in the observation period were judged to be treatment related, but unrelated to H3K27M-vac; higher grade treatment-related toxicities have not occurred.

### H3K27M-vac induced neopeptide-specific immune responses

We observed H3K27M-vac-induced peripheral T cell immune responses defined by mutation-specific interferon (IFN)- $\gamma$  enzyme-linked immunosorbent spot (ELISpot) responses detected in peripheral blood in five of eight treated patients (62.5%; Fig. 2c). The median time to first detectable H3K27M-specific immune response was two vaccinations (median, interquartile range (IQR) 2–4), corresponding to 4 weeks (median, IQR 4–10) since the start of treatment. In four out of five responding patients, the specific ELISpot responses detected in peripheral blood decreased over time (Extended Data Fig. 1). In this eight-patient cohort, there was no apparent association between H3K27M-specific peripheral immune response and age ( $P = 0.60$ ), sex ( $P = 0.46$ ), KPI ( $P = 0.75$ ), extent of resection ( $P = 0.94$ ), tumor size ( $P = 0.08$ ), time from histological diagnosis to start of vaccination ( $P = 0.06$ ), concomitant anti-PD-1 treatment ( $P = 0.57$ ), dexamethasone intake at baseline ( $P = 0.15$ ) or HLA allelotype (Extended Data Table 2 and Extended Data Fig. 2a–c).

### Patients with immune responses showed radiographic improvement

Transient radiographic improvement defined as reduction of the axial contrast-enhancing tumor area was observed in six patients and occurred shortly after first detection of H3K27M-specific immune responses in all five patients with immune response (Fig. 3a, Extended Data Fig. 3a,b and Supplementary Figs. 2–9). Median progression-free


survival (PFS) after start of vaccination across all eight patients was 6.2 months and median OS was 12.8 months (Fig. 3b,c). One patient treated with H3K27M-vac without concomitant anti-PD-1 therapy (ID 1) showed radiographic pseudoprogression (PsPD) according to immunotherapy response assessment in neuro-oncology (iRANO) criteria within 6 weeks after first detection of mutation-specific peripheral immune response (Fig. 3a,d, Extended Data Fig. 3c and Supplementary Fig. 2). Another patient with large contrast-enhancing tumor mass at baseline and concomitant anti-PD-1 therapy (ID 8) showed an early radiographic progression followed by disease stabilization from week 22 onwards in line with a latency of 18 weeks until first detection of a mutation-specific peripheral immune response (Fig. 3e and Supplementary Fig. 9).

### H3K27M neopeptide colocalized with HLA class II-DR

Proximity ligation assay (PLA) of formalin-fixed paraffin-embedded (FFPE) primary tumor tissue of seven patients for which tissue was available demonstrated that the H3K27M neopeptide colocalizes with HLA class II-DR expressed by glial fibrillary acidic protein (GFAP)-expressing tumor cells as well as single ionized calcium-binding adaptor molecule 1 (IBA1)-positive professional antigen-presenting cells (APCs) in all seven patients (Fig. 4a–c and Extended Data Figs. 4a–c and 5c–h,j–o), suggesting presentation of the H3K27M neopeptide and restimulation of H3K27M-specific tumor-infiltrating HLA-DR-restricted T cells. Immunohistochemistry showed a clear interindividual heterogeneity of MHC class II-DR expression ranging from 22% to 85% positive cells as well as PLA signal intensity (295–2,100 spots per visual field) with the two patients experiencing the most favorable outcome after detection of a H3K27M-specific peripheral immune response (ID 1 and ID 8) showing top scores of 82% and 85% MHC class II-DR positive cells and 2,100 and 1,937 PLA spots per visual field, respectively (Fig. 4d,e, Extended Data Figs. 4h and 5a,b,i and Supplementary Fig. 10).


### Mutation-specific immune responses were CD4<sup>+</sup> T cell-dominated

In vitro restimulation of peripheral CD4<sup>+</sup> and CD8<sup>+</sup> T cells with H3 mutant peptide (H3-mut) or wild-type peptide (H3-wt) revealed that




**Fig. 3 | Clinical response to H3K27M-vac.** **a**, Tumor size in mm<sup>2</sup> as a function of time in months from start of vaccination. Size determined by product of maximal orthogonal diameters on T1-weighted contrast-enhanced MRI imaging. Dots indicate measurements that are considered measurable by iRANO criteria (cerebral lesion with diameter >10 mm). **b, c**, PFS (**b**) and OS (**c**) since the start of vaccination. **d**, T1-weighted with contrast enhancement (CE) MRI sequences

of PsPD of patient ID 1 at baseline, week 10 and week 34. White arrows indicate tumor lesion with PsPD at week 10. **e**, T1-weighted with CE MRI series of patient ID 8 with early progression between baseline and week 12 followed by disease stabilization concurrent to first detectable H3K27M-specific immune response in peripheral blood in week 18.



**Fig. 4 | H3K27M neopeptide colocalizes with HLA class II-DR on tumor cells and myeloid cells.** **a–c**, PLA of primary tumor tissue of patient ID 1 (top) and ID 8 (bottom) with H3K27M and HLA-DR antibodies (red) in combination with 4',6-diamidino-2-phenylindol (DAPI) nuclear staining (blue) alone (**a**), co-staining with GFAP (green) (**b**) and co-staining with IBA1 (green) (**c**). All PLAs were repeated independently twice with similar results. Scale bar in white,

30 μm; in gray, 10 μm. **d**, Pearson correlation of PLA spots per visual field with immunohistochemistry score of HLA-DR expression across seven patients with available FFPE tissue. A two-sided *t*-test was used. **e**, Result of automated segmentation following rolling ball background subtraction, filtering with Gaussian blur and maxima detection. Scale bar in white, 30 μm.



**Fig. 5 | H3K27M-specific immune responses are CD4<sup>+</sup> T cell-mediated.**  
**a**, Suppression of H3K27M-specific IFN- $\gamma$ -ELISpot response by anti-MHC class II antibody (anti-MHC II) ( $n = 2$  biologically independent experiments (BIEs)), but not by anti-MHC class I antibody (anti-MHC I) ( $n = 3$  BIE) compared to baseline ( $n = 3$  BIE) 18 ( $P = 0.002$ ;  $P = 0.008$ , top to bottom) and 22 ( $P = 0.001$ ;  $P = 0.006$ , from top to bottom) weeks since start of H3K27M-vac treatment in patient ID 1. Two-sided  $t$ -test, not adjusted for multiple comparisons. Dots mark individual data points, bar plots show the mean and error bars indicate the s.d. \*\* signifies  $P < 0.01$ , \*\*\* signifies  $P < 0.001$ . **b–e**, Flow cytometry-based intracellular IFN- $\gamma$  and tumor necrosis factor (TNF)- $\alpha$  detection in H3K27M-peptide expanded PBMCs restimulated with H3-wt (**b,d**) or H3-mut (**c,e**), gated on CD4<sup>+</sup> (**b,c**) and CD8<sup>+</sup> (**d,e**) T cell subsets. **f**, Difference in percentage of TNF- $\alpha$ -expressing cells among all CD4<sup>+</sup> T cells between T cells stimulated with H3-mut and H3-wt either directly (ex vivo intracellular cytokine staining

(ICS)) or following expansion of T cells with H3K27M peptide (post-expansion ICS). Samples were analyzed from ID 1, ID 4, ID 5, ID 6, ID 7 and ID 8 at the weeks indicated. ELISpot responses in the first column are displayed as in Fig. 1d. **g–j**, H3K27M-reactive, TNF- $\alpha$ <sup>+</sup> CD4<sup>+</sup> T cells (orange) among all CD4<sup>+</sup> T cells (gray) did not comprise CD25<sup>+</sup> FoxP3<sup>+</sup> regulatory T cells. Depicted are ex vivo ICS data from patient ID 1 week 18 (**g**) and week 118 (**h**) as well as patient ID 8 week 0 (**i**) and week 18 (**j**). **k**, Clonotype proportion of the ten most abundant H3K27M-vac expanded CD4<sup>+</sup> T cells among all sequenced T cells in primary tissue, CSF and peripheral blood across different time points of patient ID 1. **l**, Motif plot of sequence similarities of the CDR3 $\beta$  region of top ten TCRs in **k** after removal of recurring CAS sequence in all ten TCRs. Overlap of CDR3 $\beta$  of TCR3, TCR4 and TCR6 detected in CSF with motif is indicated by color and underline.

H3K27M-specific immune responses are CD4<sup>+</sup> T cell-mediated and can be suppressed by MHC class II-, but not MHC class I-blocking antibodies (Fig. 5a–e). Intracellular cytokine staining of peptide-stimulated PBMCs confirmed presence of H3K27M-specific CD4<sup>+</sup> T cell responses with no evidence of H3K27M-vac-induced CD25<sup>+</sup> FoxP3<sup>+</sup> regulatory T cells across multiple patients and time points (Fig. 5f–j and Supplementary Figs. 11–14). After PsPD, three out of the top ten vaccine-induced, H3K27M-expanded CD4<sup>+</sup> T cell receptor (TCR) clonotypes from peripheral blood showing sequence similarities of the CDR3 $\beta$  region were detectable in the CSF of patient ID 1, who subsequently went into sustained complete remission for >31 months (Fig. 5k,l).

## Discussion

This first-in-human treatment with H3K27M-vac provides evidence of safety and immunogenicity against the clonal driver mutation H3K27M in patients with recurring H3K27M<sup>+</sup> DMG. While this small cohort of patients with advanced-stage DMG, individual concomitant anti-PD-1 treatment and limited availability of biomaterials, including post-treatment tumor tissue limits robust conclusions on overall efficacy, the median OS of 12.8 months following a H3K27M-specific immune response and the fact that one patient exhibited sustained complete remission for >31 months are encouraging. Three general conclusions for neoepitope-targeting peptide vaccines for the treatment of diffuse gliomas can be drawn from these results.

First, the use of long peptides, such as the 27-mer H3K27M-vac, is safe irrespective of concomitant anti-PD-1 therapy and suitable to induce mutation-specific CD4<sup>+</sup> T cell responses in patients with H3K27M<sup>+</sup> DMG. The induction of CD4<sup>+</sup> T cell-dominated immune responses by long mutation-specific peptide vaccines is similar to that observed in 28 of 30 patients in a first-in-human phase I trial of the long peptide vaccine IDH1-vac in patients with newly diagnosed astrocytomas<sup>20,21</sup>. Notably, CD4<sup>+</sup> T cell phenotyping following H3K27M-vac revealed no evidence of induction of immunosuppressive regulatory T cells. While the immunogenicity of the short peptide vaccine H3.3K27M<sub>26-35</sub> is restricted to HLA-A\*02<sup>+</sup> patients<sup>17</sup>, we provide evidence of presentation of H3K27M neopeptide on MHC class II on tumor cells and on APCs across multiple HLA types (Fig. 4). While killing activity of H3K27M-specific CD8<sup>+</sup> T cells against HLA-A\*02<sup>+</sup> tumor cells with endogenous H3.3K27M expression remains controversial<sup>17-19</sup> we have recently demonstrated that CD4<sup>+</sup> T cell interaction with peptide MHC class II in glioma-infiltrating myeloid cells is critical for the fitness of glioma-infiltrating CD8<sup>+</sup> T cells<sup>22</sup>. Further analyses in a larger clinical trial cohort will assess the suitability of MHC class II expression and neopeptide presentation in DMG as predictive markers for response to H3K27M-vac.

Second, both H3K27M-vac and IDH1-vac target clonal driver mutations in proteins that are expressed in all cells of primary and recurrent tumors and are functionally relevant for tumor growth<sup>2,23</sup>. Lack of clonality, in contrast, may explain why a peptide vaccine against EGFRvIII and EGFRvIII-targeting CAR T cells have failed to yield clinical benefits in glioblastomas<sup>24-27</sup>. In the cohort presented here, we observed initial tumor regression in six of eight patients with clinical stabilization for more than 6 months in four patients. Lack of post-treatment biopsies precluded the analysis of possible immune evasion, for instance through lack of presentation.

Third, H3K27M-vac-induced T cell clones were detected in both peripheral blood and CSF and expanded concurrently to radiographic tumor regression. Although a conclusive assessment of the diversity of H3K27M-expanded TCRs is not possible with only a few clonotypes from a single patient, motif analysis showed sequence similarities of the CDR3 $\beta$  region. H3K27M-vac induced immune responses against H3K27M across different patient HLA class II types with a latency of up to 18 weeks irrespective of concomitant immune checkpoint blockade. Although sustained mutation-specific immune responses were detected in 80% of responding patients in our cohort, the strength of H3K27M-vac-induced peripheral immune responses tended to decrease over time and in one patient (ID 5) a previously existing ELISpot response was no longer detectable immediately before tumor progression. As a consequence, administration of H3K27M-vac to patients with newly diagnosed H3K27M<sup>+</sup> DMG concomitant to standard-of-care first-line therapy could maximize its therapeutic benefit by allowing more time for CD4<sup>+</sup> T cell-mediated antitumor immunity to become effective. An active multicenter, phase I clinical trial for adult patients with newly diagnosed H3K27M<sup>+</sup> DMG integrates H3K27M-vac in combination with atezolizumab into standard-of-care radiotherapy (NCT04808245).

## Online content

Any methods, additional references, Nature Portfolio reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at <https://doi.org/10.1038/s41591-023-02555-6>.

## References

- Louis, D. N. et al. The 2021 WHO classification of tumors of the central nervous system: a summary. *Neuro. Oncol.* **23**, 1231–1251 (2021).
- Bender, S. et al. Reduced H3K27me3 and DNA hypomethylation are major drivers of gene expression in K27M mutant pediatric high-grade gliomas. *Cancer Cell* **24**, 660–672 (2013).
- Jessa, S. et al. K27M in canonical and noncanonical H3 variants occurs in distinct oligodendroglial cell lineages in brain midline gliomas. *Nat. Genet.* **54**, 1865–1880 (2022).
- Liu, I. et al. The landscape of tumor cell states and spatial organization in H3-K27M mutant diffuse midline glioma across age and location. *Nat. Genet.* **54**, 1881–1894 (2022).
- Kramm, C. M. et al. Thalamic high-grade gliomas in children: a distinct clinical subset? *Neuro. Oncol.* **13**, 680–689 (2011).
- Robison, N. J. & Kieran, M. W. Diffuse intrinsic pontine glioma: a reassessment. *J. Neurooncol.* **119**, 7–15 (2014).
- Vuong, H. G., Ngo, T. N. M., Le, H. T. & Dunn, I. F. The prognostic significance of HIST1H3B/C and H3F3A K27M mutations in diffuse midline gliomas is influenced by patient age. *J. Neurooncol.* **158**, 405–412 (2022).
- Omuro, A. et al. Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143. *Neuro. Oncol.* **20**, 674–686 (2018).
- Vinci, M. et al. Functional diversity and cooperativity between subclonal populations of pediatric glioblastoma and diffuse intrinsic pontine glioma cells. *Nat. Med.* **24**, 1204–1215 (2018).
- Jha, P. et al. Analysis of PD-L1 expression and T cell infiltration in different molecular subgroups of diffuse midline gliomas. *Neuropathology* **39**, 413–424 (2019).
- Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. *Nature* **500**, 415–421 (2013).
- McGranahan, N. et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. *Science* **351**, 1463–1469 (2016).
- Touat, M. et al. Mechanisms and therapeutic implications of hypermutation in gliomas. *Nature* **580**, 517–523 (2020).
- Cacciotti, C. et al. Immune checkpoint inhibition for pediatric patients with recurrent/refractory CNS tumors: a single institution experience. *J. Neurooncol.* **149**, 113–122 (2020).
- Majzner, R. G. et al. GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. *Nature* **603**, 934–941 (2022).
- Martínez-Vélez, N. et al. The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models. *Nat. Commun.* **10**, 2235 (2019).
- Mueller, S. et al. Mass cytometry detects H3.3K27M-specific vaccine responses in diffuse midline glioma. *J. Clin. Invest.* **130**, 6325–6337 (2020).
- Ochs, K. et al. K27M-mutant histone-3 as a novel target for glioma immunotherapy. *Oncoimmunology* **6**, e1328340 (2017).
- Immisch, L. et al. H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2<sup>+</sup> patients with diffuse midline glioma. *J. Immunother. Cancer* <https://doi.org/10.1136/jitc-2022-005535> (2022).
- Platten, M. et al. A vaccine targeting mutant IDH1 in newly diagnosed glioma. *Nature* **592**, 463–468 (2021).
- Schumacher, T. et al. A vaccine targeting mutant IDH1 induces antitumor immunity. *Nature* **512**, 324–327 (2014).
- Kilian, M. et al. MHC class II-restricted antigen presentation is required to prevent dysfunction of cytotoxic T cells by blood-borne myeloids in brain tumors. *Cancer Cell* **41**, 235–251 (2023).
- Bunse, L. et al. Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate. *Nat. Med.* **24**, 1192–1203 (2018).
- Reardon, D. A. et al. Rindopepimut with bevacizumab for patients with relapsed EGFRvIII-expressing glioblastoma (ReACT): results of a double-blind randomized phase II trial. *Clin. Cancer Res.* **26**, 1586–1594 (2020).
- Weller, M. et al. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. *Lancet Oncol.* **18**, 1373–1385 (2017).

26. Goff, S. L. et al. Pilot trial of adoptive transfer of chimeric antigen receptor-transduced T cells targeting EGFRvIII in patients with glioblastoma. *J. Immunother.* **42**, 126–135 (2019).
27. van den Bent, M. J. et al. Changes in the EGFR amplification and EGFRvIII expression between paired primary and recurrent glioblastomas. *Neuro. Oncol.* **17**, 935–941 (2015).

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing,

adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2023

---

<sup>1</sup>DKTK CCU Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany. <sup>2</sup>Department of Neurology, Medical Faculty Mannheim, MCTN, Heidelberg University, Mannheim, Germany. <sup>3</sup>DKFZ-Hector Cancer Institute at University Medical Center Mannheim, Mannheim, Germany. <sup>4</sup>Immune Monitoring Unit, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg, Germany. <sup>5</sup>Helmholtz Institute for Translational Oncology (HI-TRON) Mainz, German Cancer Research Center, Mainz, Germany. <sup>6</sup>Department of Neurology, University Hospital Heidelberg, Heidelberg, Germany. <sup>7</sup>National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Heidelberg, Germany. <sup>8</sup>Department of Neuropathology, University Hospital Heidelberg, Heidelberg, Germany. <sup>9</sup>DKTK Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), Heidelberg, Germany. <sup>10</sup>Department of Neuroradiology, Heidelberg University Hospital, Heidelberg, Germany. <sup>11</sup>Department of Neurosurgery, Charité-Universitätsmedizin Berlin, Berlin, Germany. <sup>12</sup>Department of Neurology with Institute of Translational Neurology, University of Münster, Münster, Germany. <sup>13</sup>Division of Clinical Neurooncology, Department of Neurology, University Hospital Bonn, University of Bonn, Bonn, Germany. <sup>14</sup>Department of Neurosurgery, University of Munich LMU, Munich, Germany. <sup>15</sup>Institute of Cell Biology, Department of Immunology, University of Tübingen, Tübingen, Germany. <sup>16</sup>These authors contributed equally: Michael Platten, Katharina Sahm. ✉e-mail: [m.platten@dkfz-heidelberg.de](mailto:m.platten@dkfz-heidelberg.de); [k.sahm@dkfz-heidelberg.de](mailto:k.sahm@dkfz-heidelberg.de)

## Methods

### Patient selection and treatment schedule

Patients received H3K27M-vac between August 2017 and November 2022 at the University Hospitals of Heidelberg and Mannheim. Treatment was approved by the institutional review board and ethics committee. All patients provided written signed informed consent according to CARE guidelines and in compliance with the Declaration of Helsinki principles. Patients received no compensation for participation in this compassionate use program. Only adult patients of all sexes and genders with unequivocal disease progression of histologically confirmed H3K27M<sup>+</sup> DMG were offered to receive treatment with H3K27M-vac. Sex was determined based on self-report. Concomitant anti-PD-1 therapy was allowed depending on the treating physician's discretion. As anti-PD-1 therapy is not approved for the treatment of DMG in Germany, the exact anti-PD-1 drug was dependent on availability. K27M substitution was determined by immunohistochemistry, hence allowing no differentiation between mutations in H3F3A and HIST2H1B/C. Exclusion criteria included concomitant treatment with dexamethasone (or equivalent) >4 mg d<sup>-1</sup>, Karnofsky performance index (KPI) < 70 and age <18 years. All patients had received radiotherapy in combination with chemotherapy with TMZ before the start of therapy. Radiation doses and the number of chemotherapy cycles at a dose of 200 mg m<sup>-2</sup> are specified for each patient in Extended Data Table 1. Treatment consisted of vaccinations with H3K27M-vac in weeks 0, 2, 4, 6, 10, 14, 18 and 22, but was stopped in case of PD. After week 22, patients with stable disease were offered to continue vaccinations every three months until PD. MRI assessment was conducted every 12 ± 2 weeks. Patients were assessed for AEs by CTCAE v.5.0 on every visit for vaccination and every 12 weeks thereafter. According to good clinical practice, an AE was defined as any untoward medical occurrence during treatment with H3K27M-vac irrespective of causal relationship. AEs were judged to be treatment-related if the relationship to treatment was 'possible', 'probable' or 'definite'. Disease progression and events which are unequivocally related to disease progression regardless of their outcome were not considered AEs. One brief partial seizure and one brief generalized seizure were not associated with disease progression, but were judged to be disease related in analogy to most clinical trials in neuro-oncology. All remaining AEs that were considered disease related occurred less than a week before MRI that showed PD. Regimen-limiting toxicity was defined as an occurrence of any treatment-related AE >grade 2 during the treatment phase.

### H3K27M-vac treatment

H3K27M-vac consists of 300 µg H3K27M 27-mer peptide (p14-40, KAPRKQLATKAARMSAPSTGGVKKPHR) synthesized by the good manufacturing practice (GMP) facility of the University of Tübingen, Germany and was emulsified in Montanide (ISA50) by the GMP facility at the University Hospitals of Heidelberg and Mannheim, Germany at most 24 h before application as described elsewhere<sup>20</sup>. H3K27M-vac was injected subcutaneously into the abdominal skin or thigh using 20-gauge needles or 21-gauge needles. The place for the subsequent injections were as close as possible to the previous injection site for all vaccinations. Ideally, the same draining lymph node was targeted for all the vaccinations. In cases of unacceptable local site reactions to the vaccination or imiquimod, the injection sites were changed but were still as close as possible to the original injection site. In such a case, subsequent vaccinations were applied to this newly chosen vaccination site (Extended Data Fig. 1a). At 15 min after injection topical imiquimod (5%, Aldara; one sachet) was applied to an area of 5 × 5 cm around the site of injection of the vaccine and sealed with 5 × 5 cm of opsite flexifix (Smith&Nephew, product no. 7478029). Patients were instructed to leave Aldara on the skin for approximately 8 h and to wash the area where Aldara was applied with mild soap and water afterwards. At 24 h after vaccination patients applied another sachet of Aldara and washed the area approximately 8 h afterwards as described above. Labour LS

s.e. & Co. in Germany performed quality controls for content, sterility and absence of endotoxin for each emulsion.

### Disease assessment

Clinical status was assessed during patient visits by a clinical neuro-oncologist. MRI assessment, including diagnosis of PsPD, applied the iRANO criteria on standardized MRIs that were obtained at least every 3 months. As in the NOA16 study<sup>20</sup>, PsPD was defined as an increase in the size of the tumor on T2-FLAIR MRI sequences and/or the new appearance or enlargement of contrast-enhancing lesions followed by stabilization or regression on follow-up MRI. Tumor sizes for Fig. 3a were determined by the product of maximal orthogonal diameters on T1-weighted contrast-enhanced MRI imaging and cerebral lesions were classified into measurable and non-measurable lesions based on iRANO criteria (cerebral lesion with both maximal orthogonal diameters >10 mm were classified as measurable).

### PBMC isolation

Heparinized blood from patients was diluted with phosphate-buffered saline (PBS) followed by density-gradient centrifugation (800 g without brake at room temperature) in Leucosep tubes (Greiner Bio-One) that contained Biocoll Separation Solution (Biochrom). Isolated PBMCs were subsequently frozen in 50% freezing medium A (60% X-Vivo20, 40% fetal calf serum (FCS)) and 50% medium B (80% FCS and 20% dimethylsulfoxide) and stored in liquid nitrogen at -140 °C until analysis.

### IFN-γ ELISpot assays of PBMCs

After hydrophilization with 35% ethanol, ELISpot HTS plates with white-bottom (Millipore, Merck, MSIPS4W10) were coated overnight at 4 °C with anti-human IFN-γ (1-D1K, Mabtech, 3420-3-250) and blocked with X-Vivo20 (Lonza) containing 1% BSA. PBMCs were thawed, rested in X-Vivo20 medium for 16 h, plated at 3 or 4 × 10<sup>5</sup> cells per well as indicated and stimulated with 100 µl peptide solution at a concentration of 20 µg ml<sup>-1</sup>. Mutant H3K27M (p14-40, KAPRKQLATKAARMSAPSTGGVKKPHR), wild-type H3 (p14-40, KAPRKQLATKAARKSAPSTGGVKKPHR) or MOG (p35-55, MEVGWYRPPFSRVVHLYRNGK) at equal concentrations were used for stimulation. Aqua ad iniectabilia (Braun) with 10% dimethylsulfoxide (vehicle) at equal volume to peptide solution were used as negative controls and 1 µg staphylococcal enterotoxin B (Sigma-Aldrich) per well as well as 0.05 µg CMV with 0.05 µg AdV per well were used as positive controls. In selected experiments, 10 µg ml<sup>-1</sup> MHC I (W6-32) or 90 µg ml<sup>-1</sup> MHC II (Tü39) blocking antibodies were added to peptide-stimulated wells. After 40 h of incubation, biotinylated anti-human IFN-γ antibodies (7-B6-1, Mabtech, 3420-6-250), streptavidin-ALP (Mabtech, 3310-10-1000) and ALP color development buffer (Bio-Rad, 170-6432) were used for detection of IFN-γ-producing cells. An ImmunoSpot Analyzer (ImmunoSpot/CTL Europe) was used for quantification of spot counts. Measurements were performed in triplicate with rare exceptions where duplicates had to be used due to low cell numbers. T cell responses were defined as a significantly higher number of s.f.u. after stimulation with K27M-mutant H3 compared to wild-type H3, as assessed by a two-sided *t*-test with a false discovery rate of 5% as determined by a two-stage step-up method of Benjamini Krieger and Yekutieli, imposed for each patient individually.

### Flow cytometry

T cell cytokine secretion was measured using flow cytometry-based ICS ex vivo and after a 2-week in vitro restimulation. Briefly, PBMCs from a pre- or post-vaccination time point were thawed, rested overnight at 2–10 × 10<sup>6</sup> cells ml<sup>-1</sup> in cytokine-free X-Vivo20 (Lonza, BE04-380Q) and on the next day restimulated either immediately (ex vivo ICS, 1 × 10<sup>6</sup> PBMCs per setup) or after in vitro expansion (0.4 × 10<sup>6</sup> cells). PBMCs were stimulated for 6 h with H3K27M-mut or H3K27M-wt peptide at 20 µg ml<sup>-1</sup>. Unstimulated cells and PMA/ionomycin (0.05 µg ml<sup>-1</sup> and



1  $\mu\text{g ml}^{-1}$ -stimulated cells served as positive and negative controls, respectively. After 1 h of incubation, protein transport inhibitor brefeldin A (GolgiPlug, BD, 555029) was added to each well at a 1:1,000 dilution. At the end of restimulation, cells were collected, incubated with a live-dead discriminator (Fixable Viability Dye APC-R700 in PBS, Invitrogen, 564997) and stained with extracellular backbone antibodies (CD3-Fitc, clone HIT3a, BD, 561802), CD4-BV605 (clone SK3, BD, 565998), CD8-PerCP-Cy5.5 (clone RPA-T8, Invitrogen, 45-0088-42) and either CD45RA-APC-H7 (clone 5H9, BD, 561212), CCR7-BV711 (clone 150503, BD, 566602), PD-1-PE (clone EH12.1, BD, 560795) or CD25-BV605 (clone 2A3, BD, 562660) and HLA-DR-APC-H7 (clone G46-6, BD, 561358) in FACS buffer (PBS + 2% FCS, Biochrom). Subsequently, intracellular staining was performed with IFN- $\gamma$ -BV421 (clone, 4S.B3, BD, 564791) and TNF- $\alpha$ -APC (clone, Mab11, BioLegend, 502912) and FoxP3-PE (clone 259/C7, BD, 560046) antibodies using Cytotif/ Cytoperm reagents (BD Biosciences) according to the manufacturer's instructions. Staining of expanded cells was limited to backbone antibodies and intracellular staining of IFN- $\gamma$  and TNF- $\alpha$ . Staining was carried out at 4 °C protected from light. All antibodies used have been titrated to achieve optimal signal to noise ratios. Cells were acquired on a BD FACS Lyric and analyzed using FlowJo analysis software v.10.8.1 (Extended Data Fig. 5).

### Proximity ligation assay

Baseline paraffin-embedded glioma tissue was used for PLA as described in Bunse et al.<sup>28</sup> H3 wild-type glioblastoma tissue from the archives of neuropathology were obtained with approval by the institutional review boards (Ethikkommission) to serve as negative control for PLA staining. Nonlinear adjustment (gamma changes) was used for visualization. Immunofluorescence co-staining was performed using mouse monoclonal anti-human GFAP (1:2,000 dilution, Cell Signaling Technology, 3670), rabbit polyclonal anti-human IBA1 (1:100 dilution, Wako, 019-19741), and secondary antibodies used were donkey anti-mouse Alexa Fluor 488 and donkey anti-rabbit Alexa Fluor 488 (all 1:300 dilution, Molecular Probes, Invitrogen, A-21202 and A-21206). For segmentation of PLA spots and nuclei an in-house developed macro for the ImageJ platform was used. Background was subtracted using the rolling ball background subtraction, Gaussian blur was used for filtering and foci as well as nuclei were segmented using the Find Maxima tool.

### Next-generation HLA typing

The QIAamp DNA Blood Mini kit (QIAGEN) was used to isolate genomic DNA from PBMCs of patients. A total of 100  $\mu\text{l}$  DNA solution with a concentration of at least 20 ng  $\mu\text{l}^{-1}$  was submitted at room temperature for high-resolution HLA typing to DKMS, Germany. Briefly, at DKMS, long-range PCRs were performed, amplicons were fragmented and used for next-generation sequencing on an Illumina MiSeq device. The full HLA class I gene and exons 2–5 of HLA class II genes were analyzed using the NGSengine (GenDx) software. Depending on the resolution, typing results were delivered either as G-code or MAC/NMDP-code.

### MHC II immunohistochemistry

Immunohistochemical analysis was carried out on 3- $\mu\text{m}$  thick FFPE tissue sections affixed onto StarFrost Advanced Adhesive slides (Engelbrecht), followed by drying at 80 °C for 15 min. Immunohistochemistry was conducted using a BenchMark Ultra immunostainer (Ventana Medical Systems). The slides were pretreated with Cell Conditioning Solution CC1 (Ventana Medical Systems) for 32 min at room temperature. The primary antibody (MHC II, 1:100 dilution, clone CR3/43, DAKO, Agilent) was incubated at 37 °C for 32 min and then the Ventana standard signal amplification and UltraWash steps were performed. Counter-staining was carried out with hematoxylin for 4 min, followed by bluing reagent for 4 min. The visualization of the immunostaining was achieved using the UltraView Universal DAB Detection kit (Ventana Medical Systems).

Scanning of the stained slides was accomplished using the Aperio AT2 Scanner (Aperio Technologies). QuPath (v.0.2.3) software was utilized for image analysis, which involved determining the total number of tumor cells within selected regions based on nuclear hematoxylin staining, as well as quantifying the total number of MHC II-positive cells in each image. The primary read out was determined by calculating the percentage of MHC II-positive cells/nuclei from each image.

### Peptide-based T cell expansion assay

PBMCs were expanded under exposure to mutant H3K27M (p14-40) peptide to enrich peptide-reactive T cell clones. Briefly, cells were thawed, transferred into X-Vivo20 (Lonza, BE04-380Q) medium supplemented with 2% AB serum (Sigma, H4522) and rested overnight as described above. On day 1, cell suspensions were adjusted to  $1 \times 10^6$  cells  $\text{ml}^{-1}$  and half of the available volume was plated at 500  $\mu\text{l}$  per well into a 24-well plate. All remaining cells were plated at the same density in a second 24-well plate. Individual wells were pulsed with either (1) 4  $\mu\text{g ml}^{-1}$  H3-mut (p14-40), (2) 4  $\mu\text{g ml}^{-1}$  H3-wt (p14-40) or (3) no peptide to control for unspecific expansion. Both plates were placed in a 37 °C CO<sub>2</sub> incubator. After 4 h, non-adherent cells of the plate that was not pulsed with peptide were plated on top of peptide-pulsed cells at a final concentration of  $1 \times 10^6$  cells  $\text{ml}^{-1}$  and per well.

Cultures were supplemented with cytokine-containing medium on day 4, 7, 9 and 11 by replacing half of the medium per well (final cytokine concentrations per well were 50 IU  $\text{ml}^{-1}$  interleukin (IL)-2 (Novartis), 25 ng  $\text{ml}^{-1}$  IL-7 (Miltenyi, 130-095-367) and 25 ng  $\text{ml}^{-1}$  IL-15 (Miltenyi, 130-095-760)). On day 13–15, cells were transferred into cytokine-free medium and on the following day, peptide-specific expansion of T cells was verified by IFN- $\gamma$  ELISpot or ICS. IFN- $\gamma$  ELISpot assays were performed as described previously<sup>20</sup>. Briefly, cells were plated at a density of  $5 \times 10^4$  cells per well and restimulated with 10  $\mu\text{g ml}^{-1}$  mutant H3K27M (p14-40) peptide, 10  $\mu\text{g ml}^{-1}$  wild-type H3 (p14-40) peptide, left unstimulated as a negative control or exposed to PMA/ionomycin (0.02  $\mu\text{g ml}^{-1}$  and 1  $\mu\text{g ml}^{-1}$ ) as a positive control. The assay was stopped after 44 h and spots were quantified using an ImmunoSpot Analyzer (Cellular Technology).

### TCR $\beta$ deep sequencing

Genomic DNA from tissue, blood or CSF of patient ID 1 was isolated using the DNeasy Blood and Tissue kit (QIAGEN, 69504). Libraries for TCR  $\beta$ -chain deep sequencing were prepared using the hsTCRB kit V4b (Adaptive Biotechnologies) according to the manufacturer's protocol and sequenced on an Illumina MiSeq device. Sequencing was performed by the Genomics & Proteomics Core Facility (German Cancer Research Center). Data were processed (demultiplexing, trimming, gene mapping) using the immunoSEQ platform from Adaptive Biotechnologies. Motif analysis was carried out using the XSTREME Tool<sup>29</sup> after removing the recurring CAS sequence from all top ten TCRs from TCR $\beta$  deep sequencing. Shuffled input sequences were used as control sequences.

### Statistical analysis

All statistical analyses were carried out in R v.3.6.1 and used a significance level of 5%. Association of patient characteristics with H3K27M-specific immune responses were assessed by Fisher's exact test. The R software packages used to calculate statistics and to illustrate the data were grid\_3.6.1, stats\_3.6.1, graphics\_3.6.1, grDevices\_3.6.1, utils\_3.6.1, datasets\_3.6.1, methods\_3.6.1, base\_3.6.1, reshape2\_1.4.3, survival\_3.2-13, survminer\_0.4.9, ggpubr\_0.2.5, magrittr\_2.0.3, ggplot2\_3.3.2, swmplot\_1.2.0, circlize\_0.4.9, RColorBrewer\_1.1-2, ComplexHeatmap\_2.5.1 and openxlsx\_4.1.4.

### Reporting summary

Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

## Data availability

The primary data that support the findings of this study are not openly available due to patient privacy. Access can be granted by contacting K.S. (k.sahm@dkfz.de) and requires a data-access agreement; requests will be replied to within 4 weeks. All primary data are stored on the controlled access repository of the University Hospital Mannheim. Referenced datasets were not used in the study. Source data are provided with this paper.

## References

28. Bunse, L. et al. Proximity ligation assay evaluates IDH1R132H presentation in gliomas. *J. Clin. Invest.* **125**, 593–606 (2015).
29. Grant, C. E. & Bailey, T. L. XSTREME: comprehensive motif analysis of biological sequence datasets. Preprint at *bioRxiv* <https://doi.org/10.1101/2021.09.02.458722> (2021).

## Acknowledgements

We express our gratitude to the patients and their families. We acknowledge the support of the DKFZ Genomics, Imaging and Cytometry Core Facility as well as the NCT Immune Monitoring Team. We acknowledge the data storage service SDS@hd supported by the Ministry of Science Germany. This study was supported by the Hertie Foundation (P1200013 to K.S.), the Helmholtz Institute for Translational Oncology HI-TRON (to E.W.G., M.P. and K.S.), the German Research Foundation (EB 187/8-1 to N.G., project 445549683, SFB1366-TPC01 to K.S. and M.P., project 39404578, GRK2727-TPB1.1 to M.P. and K.S., project 404521405, SFB1389-TPB06 to M.O.B. and K.S. and SFB1389-TPB01 to M.P.), the Baden-Württemberg-Stiftung (BWST\_ISF2018-046) to M.P. and the Rolf Schwiete Foundation (2021-009) to L.B. and M.P. and the German Cancer Aid, project 70113456 to K.S. and M.P. K.L. is funded by the Helmholtz International Graduate School.

## Author contributions

N.G. treated patients, gathered patient data, performed and analyzed PLAs, performed statistical analyses of patient data, including survival analyses, interpreted data, conceptualized and wrote the paper with input from all co-authors. I.P. and K.L. performed and analyzed immunogenicity assays, FACS analyses and HLA typing. T.B. and E.W.G. performed and analyzed TCR $\beta$  sequencing. L.B. treated patients, performed translational analyses, analyzed and interpreted data. I.M., T.K., P.V., O.M.G., U.H., J.T., F.W. and W.W. treated patients

and interpreted data. M.O.B., P.E. and M.B. performed and assessed neuroradiological examinations. A.S., F.S. and A.v.D. performed and interpreted neuropathological analysis of tumor material. K.J., I.H. and S.J. performed translational analyses. M.D. synthesized peptides and provided the GMP facility for generating peptide emulsion. K.S. and M.P. conceptualized the project, treated patients, interpreted data and conceptualized and wrote the paper with input from all co-authors.

## Funding

Open access funding provided by Deutsches Krebsforschungszentrum (DKFZ).

## Competing interests

M.P. and E.W.G. are founders of Tcelltech and inventors of associated intellectual property related to glioma-reactive T cell receptors (patent no. WO2022200456A1). M.P. and W.W. are inventors of associated intellectual property related to IDH1R132H vaccine (patent nos. EP2800580B1 and US10161940B2). M.P., K.S. and L.B. are inventors of associated intellectual property related to H3K27M vaccines (patent nos. EP3118217A1 and US20180155403A1). U.H. received speakers and/or advisory board honoraria from Medac, Janssen and Bayer. The remaining authors declare no competing interests.

## Additional information


**Extended data** is available for this paper at <https://doi.org/10.1038/s41591-023-02555-6>.

**Supplementary information** The online version contains supplementary material available at <https://doi.org/10.1038/s41591-023-02555-6>.

**Correspondence and requests for materials** should be addressed to Michael Platten or Katharina Sahm.

**Peer review information** *Nature Medicine* thanks John Sampson and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Primary Handling Editor: Ulrike Harjes, in collaboration with the *Nature Medicine* team.


**Reprints and permissions information** is available at [www.nature.com/reprints](http://www.nature.com/reprints).



**Extended Data Fig. 1 | IFN̳-ELISpot responses for all 8 patients over time.**


Spot forming units (SFU) per  $4 \times 10^5$  PBMCs after restimulation with MOG, H3-wt and H3-mut. Dots mark individual data points, bar plots the mean and error bars

the SD ( $n = 3$  BIE for all patients, conditions and time points except for ID2 week 0, 4, 14, 18, where  $n = 2$  BIE). Yellow background indicates the time period of concomitant anti-PD-1 therapy.




**Extended Data Fig. 2 | Distribution of tumor size, beginning of vaccination and age between patients with immune response and patients without response at baseline.** Distribution of tumor size in mm<sup>2</sup> determined by product of maximal orthogonal diameters on T1 weighted contrast enhanced

MRI imaging (a) time between histological diagnosis and start of vaccination in days (b) and patient age in years at start of vaccination (c) between patients with H3K27M specific immune response and patients without H3K27M specific immune response.



**Extended Data Fig. 3 | Longitudinal course of all tumor diameters and pseudoprogression in ID 1. a, b** Tumor size in mm<sup>2</sup> (a) and relative to baseline before start of vaccination (b) as a function of time in months from start of vaccination. Size determined by product of maximal orthogonal diameters on T1 weighted contrast enhanced (CE) MRI imaging. Dots indicate measurements


that are considered measurable by iRANO criteria (that is cerebral lesion with diameters > 10 mm) and stars non-measurable lesions by iRANO criteria. c, Coronal T1-weighted CE sequences (top) and fluid-attenuated inversion recovery sequences (bottom) of PsPD of patient ID 1 at baseline, week 10 and week 34. White arrows indicate tumor lesion with PsPD in week 10.



**Extended Data Fig. 4** | See next page for caption.

**Extended Data Fig. 4 | H3K27M neopeptide co-localization with HLA class II-DR on tumor cells and myeloid cells in patients ID 2, ID 3, ID 4, ID 6 and ID 7. a–c,** Proximity ligation assay (PLA) of primary tumor tissue of patient ID 2, ID 3, ID 4, ID 6 and ID 7 from top to bottom with H3K27M and HLA-DR antibodies (red) in combination with 4',6-Diamidino-2-phenylindol (DAPI) nuclear staining (blue) alone (a), co-staining with glial fibrillary acidic protein (GFAP) (green) (b) and co-staining with ionized calcium-binding adapter molecule 1 (IBA1) (green) (c).

Scale bar in white = 30  $\mu\text{m}$ ; in gray = 10  $\mu\text{m}$ . **e, f,** Automated segmentation of PLA spots (e) and nuclei (f) following rolling ball background subtraction, filtering with gaussian blur and maxima detection of visual field in a. Scale bar in gray = 10  $\mu\text{m}$ . **f, g,** PLA as in a and co-staining as in b of H3-wildtype glioblastoma. Scale bar in white = 30  $\mu\text{m}$ . **h,** Pearson correlation of PLA spots per cell with IHC score of HLA-DR expression across 7 patients with available FFPE tissue. Two-sided t-Test was used.



**Extended Data Fig. 5 | PLA segmentation and single channels of PLA images of patient ID 1 and ID 8.** **a,b,i**, Automated segmentation of PLA spots (a) and nuclei (b, i) of ID 1 and ID 8 following rolling ball background subtraction, filtering with gaussian blur and maxima detection. Scale bar in white = 30  $\mu\text{m}$ .

**c-h,j-o**, Single channels of PLA with co-stainings as indicated on the left for ID 1 and ID 8 from images in Fig. 4a–c. Scale bar in gray = 10  $\mu\text{m}$ . All PLAs were repeated independently two times with similar results.



**Extended Data Table 1 | Quantitative patient characteristics**

Patient ID	ID 1	ID 2	ID 3	ID 4	ID 5	ID 6	ID 7	ID 8	mean	standard deviation
Age at start of vaccination	28.9	34.6	18.3	23.7	25.7	29.9	33.7	29.1	28.0	5.3
Dexamethasone dose at start of vaccination in mg/d	0	0	2	2	0	4	0	0	1.0	1.5
Product of maximal orthogonal tumor diameters at start of vaccination mm <sup>2</sup>	61	28	49	61	1621	271	615	1083	474	594
Total # of vaccinations received	20	12	6	9	10	5	6	7	9.4	4.9
# of vaccinations to specific immune response in weeks	2	na	2	na	7	na	2	6	3.8	2.5
Time to H3 K27M-vac specific immune response in weeks	4	na	4	na	22	na	4	18	10.4	8.9
Total dose of radiation in Gy prior to start of vaccination	59.2	60.0	60.0	60.0	54.0	54.0	60.0	60.0	58.2	2.9
Dose of radiation in Gy per fraction of radiation prior to start of vaccination	3.2	2.0	2.0	2.0	1.8	1.8	2.0	2.0	2.1	0.5
Total dose of re-radiation after start of vaccination	n.a.	2x 36 Gy	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
Chemotherapy with TMZ (75 mg/m <sup>2</sup> BSA daily) concomitant to radiation	yes	yes	yes	yes	yes	yes	yes	Yes	n.a.	n.a.
Number of chemotherapy cycles with TMZ (200mg/m <sup>2</sup> BSA) prior to start of vaccination	0	6	4	0	0	2	6	6	3	2.8
# of chemotherapy cycles with CCNU (110mg/m <sup>2</sup> BSA) prior to start of vaccination	0	0	0	0	0	0	1	0	0.13	0.35
# of concomitant chemotherapy cycles with CCNU (110mg/m <sup>2</sup> BSA)	0	0	0	0	0	0	3	0	0.38	1.06
# of cycles of concomitant therapy with pembrolizumab (2mg/kg bw q21d)	0	48	0	0	0	0	0	7	6.88	16.8
# cycles of concomitant therapy with nivolumab (360mg q21d)	0	0	0	0	6	5	0	0	1.4	2.56
# cycles of concomitant therapy with avelumab (10mg/kg bw q21d)	0	0	0	3	0	0	0	0	0.375	1.06

**Extended Data Table 2 | HLA types of patients, p-values from fisher exact test of association of HLA type and H3K27M-specific immune response**

ID	HLA-A_1	HLA-A_2	HLA-B_1	HLA-B_2	HLA-C_1	HLA-C_2	HLA-DRB1_1	HLA-DRB1_2	DQA1_2	HLA-DQB1_1	HLA-DPB1_1	HLA-DPB1_2
ID 1	03:01	31:01	07:02	15:17	07:01	07:BRXNC	13:02	15:01	06:BKNTN	06:BYMTB	02:01	04:BYMSJ
ID 2	02:01	02:01	13:02	18:01	06:02	07:01	04:01	07:DFRJ	02:BJHMF	03:BKHVH	04:BFCSW	19:BHHE
ID 3	29:02	30:01	13:02	44:03	06:02	16:01	07:BMSUC	11:01	05:BZCGW	02:CGRKB	04:BYMRK	04:CEMZV
ID 4	03:01	29:01	07:05	27:05	02:CVHVF	15:05	01:CWDSV	10:DEDFB	01:CAVSX	05:CAVTD	04:DBPFU	04:DBPFU
ID 5	03:01	11:01	41:01	52:01	12:02	17:01	04:BDXPM	15:BFBXD	03:DMFHY	04:CETHX	04:DMAFX	04:DMAFX
ID 6	02:02	03:01	35:01	41:01	04:01	17:01	04:02	04:05	02:BMSTT	03:BMRBV	11:AWXGR	236:01
ID 7	01:01	24:02	38:01	51:01	12:03	16:02	15:01	15:01	06:BSBZX	06:BSBZX	04:BYMSJ	04:BYMSJ
ID 8	03:01	03:01	07:02	44:05	02:CVHVF	07:DCGFH	11:04	15:ADHVT	05:BZCGW	03:DBPFR	02:CWTWR	04:DBPFU
<b>p-value</b>	<b>0.88</b>		<b>0.59</b>		<b>0.98</b>		<b>0.60</b>		<b>0.86</b>	<b>1.00</b>	<b>0.60</b>	

G-codes are listed if typization exactly matched one G-code. For cases with shorter allele-strings (that is less alleles than G-code) or for cases with longer allele-strings (that is more possible results) NMDP-code is listed. Two-sided t-Test statistics was used.

## Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

### Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a | Confirmed

- The exact sample size ( $n$ ) for each experimental group/condition, given as a discrete number and unit of measurement
- A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- The statistical test(s) used AND whether they are one- or two-sided  
*Only common tests should be described solely by name; describe more complex techniques in the Methods section.*
- A description of all covariates tested
- A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
- A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
- For null hypothesis testing, the test statistic (e.g.  $F$ ,  $t$ ,  $r$ ) with confidence intervals, effect sizes, degrees of freedom and  $P$  value noted  
*Give  $P$  values as exact values whenever suitable.*
- For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
- For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
- Estimates of effect sizes (e.g. Cohen's  $d$ , Pearson's  $r$ ), indicating how they were calculated

*Our web collection on [statistics for biologists](#) contains articles on many of the points above.*

### Software and code

Policy information about [availability of computer code](#)

Data collection | Microsoft Excel Version 16.16.14 was used for patient data collection

Data analysis | Analysis was performed with R version 3.6.1.

R packages:  
base packages:  
grid\_3.6.1  
stats\_3.6.1  
graphics\_3.6.1  
grDevices\_3.6.1  
utils\_3.6.1  
datasets\_3.6.1  
methods\_3.6.1  
base\_3.6.1

additional packages:  
reshape2\_1.4.3  
survival\_3.2-13  
survminer\_0.4.9  
ggpubr\_0.2.5  
magrittr\_2.0.3

ggplot2\_3.3.2  
 swimplot\_1.2.0  
 circlize\_0.4.9  
 RColorBrewer\_1.1-2  
 ComplexHeatmap\_2.5.1  
 openxlsx\_4.1.4  
  
 Flow Jo version 10.8.1  
  
 ImageJ version 1.53

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio [guidelines for submitting code & software](#) for further information.

## Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our [policy](#)

The data that support the findings of this study are not openly available due to patient privacy and are available from the corresponding author upon reasonable request. They are stored on the controlled access repository of the University Hospital Mannheim.

## Human research participants

Policy information about [studies involving human research participants and Sex and Gender in Research](#).

Reporting on sex and gender

Both sex and gender were registered based on self reporting and all among our 8 patients there were no differences in reported sex and gender. We analyzed whether immunogenicity of H3 K27M-vac was associated with sex or gender, but did neither expect nor find an association.

Population characteristics

Covariate-relevant population characteristics are stated in Figure 1a, Extended Data Table 1 and 2 :  
 Age at start of vaccination (safety and immunogenicity might depend on patient age)  
 Sex (safety and immunogenicity might depend on patient sex)  
 HLA Type (safety and immunogenicity might depend on patient HLA type)  
 tumor diameter at start of vaccination as judged by product of maximal orthogonal tumor diameter on T1 weighted MRI with contrast enhancement (safety and immunogenicity might depend on tumor diameter)  
 tumor localization (safety and immunogenicity might depend tumor localization)  
 time of initial diagnosis (PFS and OS might depend tumor localization)  
 Karnofsky Performance Index (PFS and OS might depend tumor localization)  
 Oral dexamethasone intake at start of therapy (safety and immunogenicity might depend dexamethasone intake at start of therapy)  
 Extend of resection at initial diagnosis (PFS and OS might depend tumor localization)  
 Dose and fractionation scheme of prior radiation (PFS and OS might depend dose and fractionation scheme of prior radiation)  
 Dose and type of prior chemotherapy (PFS and OS might depend dose and type of prior chemotherapy)  
 co-morbidities (PFS and OS might depend on co-morbidities)

Recruitment

Patients were recruited by referral from clinical neurooncologists. All patients eligible for treatment as determined by the treatment plan were extensively informed about the possibility of treatment with H3K27M-vac and potential therapeutic alternatives. Only patients who provided written informed consent after sufficient time for reflection were treated with H3K27M-vac. We therefore cannot exclude self-selection bias which might be responsible for the favorable overall survival of the entire patient cohort together with the required Karnofsky performance score of above 60%. It seems unlikely that self selection had a meaningful influence on safety and immunogenicity.

Ethics oversight

Institutional review board (Ethikkommission) University Hospitals Mannheim, Heidelberg University.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

## Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

- Life sciences       Behavioural & social sciences       Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](https://www.nature.com/documents/nr-reporting-summary-flat.pdf)

# Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	We limited the sample size to eight adult patients with recurrent, histologically confirmed H3K27M+ DMG after standard therapy options and not eligible to be enrolled in the currently ongoing multicenter, phase 1 clinical trial (NCT04808245), because therapy was given on a compassionate use basis and not as part of a clinical trial. The compassionate use program was limited to a small number of patients and eight adult patients were judged to be sufficient to preliminarily assess safety and immunogenicity of H3K27Mvac in patients with progressive DMG.
Data exclusions	No data were excluded from the study.
Replication	To ensure reproducibility of our findings we carefully laid out a treatment plan, determined and reported patient characteristics that might be relevant to the effects studied. Furthermore, we described all experimental procedures in detail and will be happy to refine reporting if reviewers have questions or suggestions for improvement. All experiments were performed once unless otherwise reported. PLA was performed independently twice as indicated in legends of Figure 4 and Extended Figure 5. The attempt of replication was successful.
Randomization	Since all patients received H3K27M-vac randomization did not apply. We extensively determined and reported patient characteristics and tested for several potential covariates such as age (p=0.60), sex (p=0.46), KPS (p=0.75), extent of resection (p=0.94), tumor size (p=0.21), time from histological diagnosis to start of vaccination (p=0.06), concomitant anti-PD1 treatment (p=0.47), dexamethasone intake at baseline (p=0.15) or HLA allelotype. Nonetheless it should be noted that due to the limited number of patients absence of association does not exclude covariates.
Blinding	This was an open label treatment with both patients and treating physicians being aware of the treatment with H3K27M-vac. Efficacy assessment was explicitly not part of the analysis and would require a blinded randomized controlled clinical trial. We report the experiences with a limited number of patients threatened on a compassionate use basis.

## Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

### Materials & experimental systems

n/a	Involved in the study
<input type="checkbox"/>	<input checked="" type="checkbox"/> Antibodies
<input checked="" type="checkbox"/>	<input type="checkbox"/> Eukaryotic cell lines
<input checked="" type="checkbox"/>	<input type="checkbox"/> Palaeontology and archaeology
<input checked="" type="checkbox"/>	<input type="checkbox"/> Animals and other organisms
<input type="checkbox"/>	<input checked="" type="checkbox"/> Clinical data
<input checked="" type="checkbox"/>	<input type="checkbox"/> Dual use research of concern

### Methods

n/a	Involved in the study
<input checked="" type="checkbox"/>	<input type="checkbox"/> ChIP-seq
<input type="checkbox"/>	<input checked="" type="checkbox"/> Flow cytometry
<input type="checkbox"/>	<input checked="" type="checkbox"/> MRI-based neuroimaging

## Antibodies

Antibodies used	Elispot: anti-human IFN (1-D1K, Mabtech, 3420-3-250), anti-human IFN (7-B6-1, Mabtech, 3420-6-250); Flow Cytometry: CD3-Fitc (HIT3a, BD, 561802), CD4-BV605 (clone SK3, BD, 565998), CD8-PerCP-Cy5.5 (clone RPA-T8, Invitrogen, 45-0088-42), CD45RA-APC-H7 (clone 5H9, BD, 561212), CCR7-BV711 (clone 150503, BD, 566602), PD1-PE (clone EH12.1, BD, 560795), CD25-BV605 (clone 2A3, BD, 562660), HLA-DR-APC-H7 (clone G46-6, BD, 561358), IFN $\gamma$ -BV421 (clone, 4S.B3, BD, 564791), TNF $\alpha$ -APC (clone, Mab11, Biolegend, 502912), FoxP3-PE (clone 259/C7, BD, 560046). PLA: mouse monoclonal anti-human GFAP (1:2000, Cell signal, 3670), rabbit polyclonal anti-human IBA-1 (1:100, Wako, 019-19741), donkey anti-mouse Alexa Fluor 488 (1:300, Molecular Probes, Invitrogen, A-21202) and donkey anti-rabbit Alexa Fluor 488 (1:300, Molecular Probes, Invitrogen, A-21206)
Validation	all antibodies are ROA reagents. Flow cytometry antibodies were titrated for optimal signal to noise ratios. Validation of FACS Antibodies: CD3-Fitc (HIT3a, BD, 561802): Barclay NA, Brown MH, Birkeland ML, et al, ed. The Leukocyte Antigen FactsBook. San Diego, CA: Academic Press; 1997. (Biology) Beverly PC, Callard RE. Distinctive functional characteristics of human "T" lymphocytes defined by E rosetting or a monoclonal anti-T cell antibody. Immunol. 1981; 11(4):329-334. (Biology) Knapp W, Dorken B, Rieber EP, et al, ed. Leukocyte Typing IV. New York: Oxford University Press; 1989:1-1208. (Biology) Lanier LL, Allison JP, Phillips JH. Correlation of cell surface antigen expression on human thymocytes by multi-color flow cytometric analysis: implications for differentiation. J Immunol. 1986; 137(8):2501-2507. (Biology) McMichael AJ, Beverly PCL, Gilks W, et al, ed. Leukocyte Typing III: White Cell Differentiation Antigens. New York: Oxford University Press; 1987. (Biology) Schlossman SF, Boumsell L, Gilks W, et al, ed. Leukocyte Typing V: White Cell Differentiation Antigens. New York: Oxford University Press; 1995. (Clone-specific)

- CD4-BV605 (clone SK3, BD, 565998):  
Bernard A, Boumsell L, Hill C. Joint report of the first international workshop on human leucocyte differentiation antigens by the investigators of the participating laboratories. In: Bernard A, Boumsell L, Dausset J, Milstein C, Schlossman SF, ed. *Leucocyte Typing*. New York, NY: Springer-Verlag; 1984:9-108.
- Engleman EG, Benike CJ, Glickman E, Evans RL. Antibodies to membrane structures that distinguish suppressor/cytotoxic and helper T lymphocyte subpopulations block the mixed leukocyte reaction in man. *J Exp Med*. 1981; 154(1):193-198. (Clone-specific: Functional assay, Inhibition).
- Evans RL, Wall DW, Platsoucas CD, et al. Thymus-dependent membrane antigens in man: inhibition of cell-mediated lympholysis by monoclonal antibodies to TH2 antigen. *Proc Natl Acad Sci U S A*. 1981; 78(1):544-548. (Immunogen: Flow cytometry, Inhibition).
- Reichert T, DeBruyere M, Deney V, et al. Lymphocyte subset reference ranges in adult Caucasians. *Clin Immunol Immunopathol*. 1991; 60(2):190-208. (Biology).
- Sattentau QJ, Dalgleish AG, Weiss RA, Beverley PC. Epitopes of the CD4 antigen and HIV infection. *Science*. 1986; 234(4780):1120-1123. (Biology).
- Wood GS, Warner NL, Warnke RA. Anti-Leu-3/T4 antibodies react with cells of monocyte/macrophage and Langerhans lineage. *J Immunol*. 1983; 131(1):212-216. (Biology).
- CD8-PerCP-Cy5.5 (clone RPA-T8, Invitrogen, 45-0088-42):  
Vardam-Kaur T, Pathangey LB, McCormick DJ, Bergsagel PL, Cohen PA, Gendler SJ. Multipeptide stimulated PBMCs generate TEM/TCM for adoptive cell therapy in multiple myeloma. *Oncotarget*. 2021 Sep 28;12(20):2051-2067.
- CD45RA-APC-H7 (clone 5H9, BD, 561212):  
Barclay NA, Brown MH, Birkeland ML, et al, ed. *The Leukocyte Antigen FactsBook*. San Diego, CA: Academic Press; 1997.
- Johnson P, Maiti A, Ng DHW. CD45: A family of leukocyte-specific cell surface glycoproteins. In: Herzenberg LA, Weir DM, Herzenberg LA, Blackwell C, ed. *Weir's Handbook of Experimental Immunology*, Vol 2. Cambridge: Blackwell Science; 1997:62.1-62.16.
- Knapp W. W. Knapp .. et al., ed. *Leucocyte typing IV : white cell differentiation antigens*. Oxford New York: Oxford University Press; 1989:1-1182.
- Picker LJ, Treer JR, Ferguson-Darnell B, Collins PA, Buck D, Terstappen LW. Control of lymphocyte recirculation in man. I. Differential regulation of the peripheral lymph node homing receptor L-selectin on T cells during the virgin to memory cell transition. *J Immunol*. 1993; 150(3):1105-1121. (Biology).
- Schwizner R. Cluster Report: CD45/CD45R. In: Knapp W. W. Knapp .. et al., ed. *Leucocyte typing IV : white cell differentiation antigens*. Oxford New York: Oxford University Press; 1989:628-634.
- CCR7-BV711 (clone 150503, BD, 566602):  
Birkenbach M, Josefsen K, Yalamanchili R, Lenoir G, Kieff E. Epstein-Barr virus-induced genes: first lymphocyte-specific G protein-coupled peptide receptors. *Nature*. 1993; 67(4):2209-2220. (Biology).
- Burgstahler R, Kempkes B, Steube K, Lipp M. Expression of the chemokine receptor BLR2/EBI1 is specifically transactivated by Epstein-Barr virus nuclear antigen 2. *Biochem Biophys Res Commun*. 1995; 215(2):737-743. (Biology). View Reference
- Kim CH, Pelus LM, White JR, Broxmeyer HE. Macrophage-inflammatory protein-3 beta/EBI1-ligand chemokine/CK beta-11, a CC chemokine, is a chemoattractant with a specificity for macrophage progenitors among myeloid progenitor cells. *J Immunol*. 1998; 161(5):2580-2585. (Biology).
- Loria MP, Dambra P, Capuzzimati L, et al. Cytokine/Chemokine H LDA8 Workshop panel report: Analysis of receptors on lymphocytes from cord blood, normal and asthmatic subjects, and HIV positive patients. *Cell Immunol*. 2005; 236(1-2):105-109. (Clone-specific: Flow cytometry).
- Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. *Nature*. 1999; 401(6754):708-712. (Biology).
- Schweickart VL, Raport CJ, Godiska R, et al. Cloning of human and mouse EBI1, a lymphoid-specific G-protein-coupled receptor encoded on human chromosome 17q12-q21.2. *Genomics*. 1994; 23(3):643-650. (Biology).
- Yanagihara S, Komura E, Nagafune J, Watarai H, Yamaguchi Y. EBI1/CCR7 is a new member of dendritic cell chemokine receptor that is up-regulated upon maturation. *J Immunol*. 1998; 161(6):3096-3102. (Biology).
- Yoshida R, Imai T, Hieshima K, et al. Molecular cloning of a novel human CC chemokine EBI1-ligand chemokine that is a specific functional ligand for EBI1, CCR7. *J Biol Chem*. 1997; 272(21):13803-13809. (Biology).
- Yoshida R, Nagira M, Imai T, et al. EBI1-ligand chemokine (ELC) attracts a broad spectrum of lymphocytes: activated T cells strongly up-regulate CCR7 and efficiently migrate toward ELC. *Int Immunol*. 1998; 10(7):901-910. (Biology).
- Yoshida R, Nagira M, Kitaura M, Imagawa N, Imai T, Yoshie O. Secondary lymphoid-tissue chemokine is a functional ligand for the CC chemokine receptor CCR7. *J Biol Chem*. 1998; 273(12):7118-7122. (Biology).
- PD1-PE (clone EH12.1, BD, 560795):  
Bennett F, Luxenberg D, Ling V, et al. Program death-1 engagement upon TCR activation has distinct effects on costimulation and cytokine-driven proliferation: attenuation of ICOS, IL-4, and IL-21, but not CD28, IL-7, and IL-15 responses. *J Immunol*. 2003; 170(2):711-718. (Biology).
- Carter L, Fouser LA, Jussif J, et al. PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2. *Eur J Immunol*. 2002; 32:634-643. (Biology).
- Dorfman DM, Brown JA, Shahsafaei A, Freeman GJ. Programmed death-1 (PD-1) is a marker of germinal center-associated T cells and angioimmunoblastic T-cell lymphoma. *Am J Surg Pathol*. 2006; 30:802-810. (Clone-specific: Immunohistochemistry). View Reference
- Freeman GJ, Long AJ, Iwai Y, et al. Engagement of PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. *J Exp Med*. 2000; 192:1027-1034. (Biology).
- Latchman Y, Wood CR, Chernova T, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. *Nat Immunol*. 2001; 2(3):261-268. (Biology).
- Nishimura H, Minato N, Nakano T, Honjo T. Immunological studies on PD-1 deficient mice: implication of PD-1 as a negative regulator for B cell responses. *Int Immunol*. 1998; 10(10):1563-1572. (Biology).
- CD25-BV605 (clone 2A3, BD, 562660):  
Bach JF. Regulatory T cells under scrutiny. *Nat Rev Immunol*. 2003; 3(3):189-198. (Biology).
- Greene WC, Leonard WJ. The human interleukin-2 receptor. *Annu Rev Immunol*. 1986; 4:69-95. (Biology).
- Jackson AL, Matsumoto H, Janszen M, Maino V, Blidy A, Shye S. Restricted expression of p55 interleukin 2 receptor (CD25) on normal

T cells. *Clin Immunol Immunopathol.* 1990; 54(1):126-133. (Biology).

Lando Z, Sarin P, Megson M, et al. Association of human T-cell leukaemia/lymphoma virus with the Tac antigen marker for the human T-cell growth factor receptor. *Nature.* 1983; 305(5936):733-736. (Biology).

Leonard WJ, Depper JM, Uchiyama T, Smith KA, Waldmann TA, Greene WC. A monoclonal antibody that appears to recognize the receptor for human T-cell growth factor; partial characterization of the receptor. *Nature.* 1982; 300(5889):267-269. (Biology).

Ng WF, Duggan PJ, Ponchel F, et al. Human CD4(+)/CD25(+) cells: a naturally occurring population of regulatory T cells. *Blood.* 2001; 98(9):2736-2744. (Biology).

Rambaldi A, Young DC, Herrmann F, Cannistra SA, Griffin JD. Interferon-gamma induces expression of the interleukin 2 receptor gene in human monocytes. *Eur J Immunol.* 1987; 17(1):153-156. (Biology).

Robb RJ, Greene WC, Rusk CM. Low and high affinity cellular receptors for interleukin 2. Implications for the level of Tac antigen. *J Exp Med.* 1984; 160(4):1126-1146. (Biology).

Schwartz R, Stein H. Cluster report: CD25. In: Knapp W. W. Knapp .. et al., ed. *Leucocyte typing IV : white cell differentiation antigens.* Oxford New York: Oxford University Press; 1989:399-403.

Sereti I, Martinez-Wilson H, Metcalf JA, et al. Long-term effects of intermittent interleukin 2 therapy in patients with HIV infection: characterization of a novel subset of CD4(+)/CD25(+) T cells. *Blood.* 2002; 100(6):2159-2167. (Biology). View Reference

Siegel JP, Sharon M, Smith PL, Leonard WJ. The IL-2 receptor beta chain (p70): role in mediating signals for LAK, NK, and proliferative activities. *Science.* 1987; 238(4823):75-78. (Biology).

Teshigawara K, Wang HM, Kato K, Smith KA. Interleukin 2 high-affinity receptor expression requires two distinct binding proteins. *J Exp Med.* 1987; 165(1):223-238. (Biology).

Urdal DL, March CJ, Gillis S, Larsen A, Dower SK. Purification and chemical characterization of the receptor for interleukin 2 from activated human T lymphocytes and from a human T-cell lymphoma cell line. *Proc Natl Acad Sci U S A.* 1984; 81(20):6481-6485. (Biology).

HLA-DR-APC-H7 (clone G46-6, BD, 561358):

Barclay NA, Brown MH, Birkeland ML, et al, ed. *The Leukocyte Antigen FactsBook.* San Diego, CA: Academic Press; 1997.

Dieckmann D, Plottner H, Berchtold S, Berger T, Schuler G. Ex vivo isolation and characterization of CD4(+)/CD25(+) T cells with regulatory properties from human blood. *J Exp Med.* 2001; 193(11):1303-1310. (Clone-specific: Flow cytometry).

Ibisch C, Pradal G, Bach JM, Lieubeau B. Functional canine dendritic cells can be generated in vitro from peripheral blood mononuclear cells and contain a cytoplasmic ultrastructural marker.. *J Immunol Methods.* 2005; 298(1-2):175-82. (Clone-specific).

Kitani A, Chua K, Nakamura K, Strober W. Activated self-MHC-reactive T cells have the cytokine phenotype of Th3/T regulatory cell 1 T cells. *J Immunol.* 2000; 165(2):691-702. (Clone-specific: Flow cytometry).

Moran TP, Collier M, McKinnon KP, Davis NL, Johnston RE, Serody JS. A novel viral system for generating antigen-specific T cells. *J Immunol.* 2008; 175(5):3431-3438. (Clone-specific: Flow cytometry).

Sorg RV, Kogler G, Wernet P. Identification of cord blood dendritic cells as an immature CD11c- population. *Blood.* 1999; 93(7):2302-2307. (Clone-specific: Flow cytometry).

IFN $\gamma$ -BV421 (clone, 4S.B3, BD, 564791):

Fonteneau JF, Le Drean E, Le Guiner S, Gervois N, Diez E, Jotereau F. Heterogeneity of biologic responses of melanoma-specific CTL. *J Immunol.* 1997; 159(6):2831-2839. (Clone-specific: Flow cytometry).

Meager A, Parti S, Barwick S, Spragg J, O'Hagan K. Detection of hybridomas secreting monoclonal antibodies to human gamma interferon using a rapid screening technique and specificity of certain monoclonal antibodies to gamma interferon. *J Interferon Res.* 1984; 4(4):619-625. (Immunogen: Immunoprecipitation, Radioimmunoassay).

Meager A. Characterization of interferons and immunoassays. In: Clemens MJ, Morris AG, Gearing AJH, ed. *Lymphokines and Interferons. A Practical Approach.* Oxford: IRL Press Ltd; 1987:105-127.

Prussin C, Metcalfe DD. Detection of intracytoplasmic cytokine using flow cytometry and directly conjugated anti-cytokine antibodies. *J Immunol Methods.* 1995; 188(1):117-128. (Methodology: Flow cytometry).

Rotteveel FT, Kokkelink I, van Lier RA, et al. Clonal analysis of functionally distinct human CD4+ T cell subsets. *J Exp Med.* 1988; 168(5):1659-1673. (Clone-specific: ELISA).

TNF $\alpha$ -APC (clone, Mab11, Biologend, 502912):

Rathjen D, et al. 1991. *Mol. Immunol.* 28:79.

Ablamunits V, et al. 2010. *Eur. J. Immunol.* 40:2891.

Enrquez J, et al. 2002. *Adv. Perit. Dial.* 18:177.

Andersson U, et al. 1999. *Detection and quantification of gene expression.* New York:Springer-Verlag.

Chen H, et al. 2005. *J. Immunol.* 175:591.

Iwamoto S, et al. 2007. *J. Immunol.* 179:1449.

Andersson U, et al. 2000. *J. Exp. Med.* 192:565.

Moormann AM, et al. 1999. *J. Infect. Dis.* 180:1987.

Zhao XJ, et al. 2003. *J. Immunol.* 170:2923.

Rieger R, et al. 2009. *Cancer Gene Ther.* 1:53-64.

Maksareekul S, et al. 2009. *Vaccine.* 28:3754

FoxP3-PE (clone 259/C7, BD, 560046):

Brunkow ME, Jeffery EW, Hjerrild KA, et al. Disruption of a new forkhead/winged-helix protein, scurfy, results in the fatal lymphoproliferative disorder of the scurfy mouse. *Nat Genet.* 2001; 27(1):68-73. (Biology).

Giovanna Roncador et al. Analysis of Foxp3 protein expression in human CD4+CD25+ regulatory T cells at a single cell level. *Eur J Immunol.* 2005; 35(Immunogen).

Wildin RS, Ramsdell F, Peake J, et al. X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. *Nat Genet.* 2001; 27(1):18-20. (Biology).

Elispot:

anti-human IFN (1-D1K, Mabtech, 3420-3-250) and anti-human IFN (7-B6-1, Mabtech, 3420-6-250):

Apostolovic D, Grundström J, Kiewiet MBG, Perusko M, Hamsten C, Starkhammar M, Paulie S, van Hage M. Th2-skewed T cells correlate with B cell response to  $\alpha$ -Gal and tick antigens in  $\alpha$ -Gal syndrome. *J Clin Invest.* 2023 Mar 15

Foord E, Arruda LCM, Gaballa A, Klynning C, Uhlin M. Characterization of ascites- and tumor-infiltrating  $\gamma\delta$  T cells reveals distinct repertoires and a beneficial role in ovarian cancer. *Sci Transl Med.* 2021 Jan 20;13(577)

PLA:  
 mouse monoclonal anti-human GFAP (1:2000, Cell signal, 3670):  
 Eng, L.F. et al. (2000) *Neurochem. Res.* 25, 1439-51.  
 Goebel, H.H. et al. (1987) *Acta. Histochem. Suppl.* 34, 81-93.  
 Jessen, K.R. et al. (1990) *Development* 109, 91-103.

rabbit polyclonal anti-human IBA-1 (1:100, Wako, 019-19741:  
 Imai, Y., Ibata, I., Ito, D., Ohsawa, K., & Kohsaka, S.: *Biochem. Biophys. Res. Commun.*, 224(3), 855(1996).  
 A Novel Geneiba1 in the Major Histocompatibility Complex Class III Region Encoding an EF Hand Protein Expressed in a Monocytic Lineage  
 Mori, I., Imai, Y., Kohsaka, S., & Kimura, Y.: *Microbiol. Immunol.*, 44(8), 729(2000).  
 Upregulated expression of Iba1 molecules in the central nervous system of mice in response to neurovirulent influenza A virus infection  
 Sasaki, Y., Ohsawa, K., Kanazawa, H., Kohsaka, S., & Imai, Y. *Biochem. Biophys. Res. Commun.*, 286(2), 292(2001).  
 Iba1 is an actin-cross-linking protein in macrophages/microglia.  
 Ahn, J.H., et al.: *Lab. Anim. Res.*, 28(3), 165 (2012).  
 Comparison of alpha-synuclein immunoreactivity in the spinal cord between the adult and aged beagle dog  
 Ide, T., et al.: *J. Vet. Med. Sci.*, 72(1), 99 (2010).  
 Histiocytic Sarcoma in the Brain of a Cat  
 Gaige, S., et al.: *Neurotoxicology*, 34, 135(2013).  
 c-Fos immunoreactivity in the pig brain following deoxyvalenol intoxication: Focus on NUCB2/nesfatin-1 expressing neurons  
 Rodriguez-Callejas, J.D. et al.: *Front. Aging Neurosci.*, 8, 315(2016).  
 Evidence of Tau Hyperphosphorylation and Dystrophic Microglia in the Common Marmoset  
 Fantin, A., et al.: *Blood*, 116(5), 829(2010).  
 Tissue macrophages act as cellular chaperones for vascular anastomosis downstream of VEGF-mediated endothelial tip cell induction

## Clinical data

Policy information about [clinical studies](#)

All manuscripts should comply with the ICMJE [guidelines for publication of clinical research](#) and a completed [CONSORT checklist](#) must be included with all submissions.

Clinical trial registration	Since the patient were treated on a compassionate use basis and not as part of a clinical trial, it was not registered on ClinicalTrials.org.
Study protocol	We provided a treatment protocol that outlines the treatment plan for patients treated with H3K27M on a compassionate use basis.
Data collection	Patients received H3K27M-vac between August 2017 and February 2023 at the University Hospitals of Heidelberg and Mannheim. Both medical centers are tertiary care centers with certified cancer centers by the German Cancer Society.
Outcomes	Safety of H3K27M-vac treatment was assessed during patient visits by a specialized neurooncologist by Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Immunogenicity was assessed by ELISpot as extensively specified in the methods section of the manuscript. MRI assessment including response assessment was done by neuroradiologists according to IRANO criteria as specified in the methods section of the manuscript.

## Flow Cytometry

### Plots

Confirm that:

- The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
- The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
- All plots are contour plots with outliers or pseudocolor plots.
- A numerical value for number of cells or percentage (with statistics) is provided.

### Methodology

Sample preparation	blood was collected in Li-Heparin tubes and processed within 6 hours of venipuncture by ficoll-density gradient centrifugation. Isolated PBMC were cryopreserved in freezing medium containing 10% DMSO and stored in a liquid nitrogen gas phase tank. Upon thawing, PBMC were rested overnight prior to any functional analysis.
Instrument	BD FACS Lyric
Software	BD FACSuite was used for aquisition, FlowJo V10 was used for analysis.
Cell population abundance	cells were analyzed post in vitro expansion and contained predominantly T cells . Viability was >93 % in all cases. Approximately 66% of CD3+ T cells were CD4+. Background in unstimulated cells was below 0.04% of CD4+ and total cytokine secreting cells were > 68%. No cytokine secretion was observed in stimulated CD8+ T cells, but both CD4 and CD8 T cells produced IFN and TNF in response to control stimulation (PMA/ionomycine)



## Gating strategy

Hierarchical gating: Exclusions of Debris (FSC-A vs SSC-A)/Exclusion of doublets (FSC-A vs FSC-W), Exclusion of dead-cells (SSC-A vs dead-cell-stain)/Definition of T cells (SSC-A vs CD3-Fitc+)/Definition of T cell subsets (CD8-PerpCP-Cy5.5 vs CD4 BV605)/ Identification of cytokine secreting cells (IFNgamma-BV421 vs TNFalpha-APC), gates were set using unstimulated control

Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.

## Magnetic resonance imaging

### Experimental design

Design type

Design specifications

Behavioral performance measures

### Acquisition

Imaging type(s)

Field strength

Sequence & imaging parameters

Area of acquisition

Diffusion MRI  Used  Not used

### Preprocessing

Preprocessing software

Normalization

Normalization template

Noise and artifact removal

Volume censoring

### Statistical modeling & inference

Model type and settings

Effect(s) tested

Specify type of analysis:  Whole brain  ROI-based  Both

Statistic type for inference (See [Eklund et al. 2016](#))

Correction

### Models & analysis

n/a | Involved in the study

Functional and/or effective connectivity

Graph analysis

Multivariate modeling or predictive analysis